Hasil Pencarian - Xavier Leleu

Perbaiki Hasil
  1. 1
    The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

    The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma oleh Arthur Bobin, Hélène Gardeney, Florence Sabirou, Cécile Gruchet, Anthony Lévy, Laly Nsiala, Laura Cailly, Cécile Tomowiak, Cécile Tomowiak, Cécile Tomowiak, Jose Torregrosa, Jose Torregrosa, Jose Torregrosa, Stéphanie Guidez, Stéphanie Guidez, Stéphanie Guidez, Xavier Leleu, Xavier Leleu, Xavier Leleu

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Understanding the multiple biological aspects leading to myeloma

    Understanding the multiple biological aspects leading to myeloma oleh Eileen M. Boyle, Faith E. Davies, Xavier Leleu, Gareth J. Morgan

    Diterbitkan 2014-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenström macroglobulinemia patients aged 65 years or less

    The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenström macroglobulinemia patients aged 65 years or less oleh Stéphanie Poulain, Isabelle Dervite, Xavier Leleu, Valérie Coiteux, Patrick Duthilleul, Pierre Morel

    Diterbitkan 2008-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2

    P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNE... oleh Xavier Leleu, Shinsuke Iida, C. Ola Landgren, Alexander Lesokhin, Eric Leip, Arthur Kudla, Gregory Finn, Lugui Qiu

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

    Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma oleh Philippe Moreau, Valerie Coiteux, Cyrille Hulin, Xavier Leleu, Helgi van de Velde, Milin Acharya, Jean-Luc Harousseau

    Diterbitkan 2008-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3

    P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3 oleh Xavier Leleu, Noopur Raje, Alexander Lesokhin, Mohamad Mohty, Ajay Nooka, Eric Leip, Sharon T. Sullivan, Andrea Viqueira, Salomon Manier

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel

    Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel oleh Xavier Leleu, Eirini Katodritou, Thomas Kuehr, Evangelos Terpos, Jo Caers, Renato Zambello, Alessandra Brescianini, Tony Liang, Sally Wetten, Sorina N. Badelita

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

    Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma oleh Paul G. Richardson, Thierry Facon, William I. Bensinger, Xavier Leleu, Frank Campana, Sandrine Macé, Marielle Chiron, Helgi van de Velde, Joseph Mikhael

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

    Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma oleh Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Helgi van de Velde, Huaibao Feng, Andrew Cakana, William Deraedt, Philippe Moreau

    Diterbitkan 2012-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment

    An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment oleh Meletios A. Dimopoulos, Joseph Mikhael, Evangelos Terpos, Xavier Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith Stockerl-Goldstein, Paul G. Richardson

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

    PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA oleh Shaji Kumar, Xavier Leleu, Katja Weisel, Rakesh Popat, Samantha Craigie, Leena Patel, Abril Oliva Ramirez, Wenzhen Ge, Qiufei MA, Christian Hampp, Sundar Jagannath

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition

    Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition oleh Mérédis Favreau, Koen Venken, Sylvia Faict, Ken Maes, Kim De Veirman, Elke De Bruyne, Xavier Leleu, Louis Boon, Dirk Elewaut, Karin Vanderkerken, Eline Menu

    Diterbitkan 2017-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

    Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. oleh Song Xu, Gaia Cecilia Santini, Kim De Veirman, Isabelle Vande Broek, Xavier Leleu, Ann De Becker, Ben Van Camp, Karin Vanderkerken, Ivan Van Riet

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Long‐term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98‐LEDGF rearrangement

    Long‐term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98‐LEDGF rearrangement oleh Maria Pilar Gallego Hernanz, José Miguel Torregrosa Diaz, Nathalie Sorel, Arthur Bobin, Elodie Dindinaud, Sabrina Bouyer, Deborah Desmier, Françoise Brizard, Xavier Leleu, Natacha Maillard, Jean‐Claude Chomel

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization.

    Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. oleh Maroulio Pertesi, Perrine Galia, Nicolas Nazaret, Maxime Vallée, Laurent Garderet, Xavier Leleu, Hervé Avet-Loiseau, Matthieu Foll, Graham Byrnes, Joel Lachuer, James D McKay, Charles Dumontet

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis

    Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis oleh Thierry Facon, Philippe Moreau, Ross Baker, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Nicole M. Armstrong, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    P886: EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL

    P886: EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL oleh Maria-Victoria Mateos, Monika Engelhardt, Xavier Leleu, Mercedes Gironella Mesa, Holger W. Auner, Michele Cavo, Meletios A. Dimopoulos, Martina Bianco, Giovanni Marino Merlo, Charles la Porte, Philippe Moreau

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    P917: SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES

    P917: SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES oleh Maria-Victoria Mateos, Monika Engelhardt, Xavier Leleu, Mercedes Gironella Mesa, Holger W. Auner, Michele Cavo, Meletios A. Dimopoulos, Martina Bianco, Giovanni Marino Merlo, Charles la Porte, Philippe Moreau

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

    Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study oleh Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Grigoriy Rekhtman, Zvenyslava Masliak, Pawel Robak, Dixie-Lee Esseltine, Huaibao Feng, William Deraedt, Helgi van de Velde, Bertrand Arnulf

    Diterbitkan 2015-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Global epigenetic regulation of microRNAs in multiple myeloma.

    Global epigenetic regulation of microRNAs in multiple myeloma. oleh Wenjing Zhang, Yaoyu E Wang, Yu Zhang, Xavier Leleu, Michaela Reagan, Yong Zhang, Yuji Mishima, Siobhan Glavey, Salomon Manier, Antonio Sacco, Bo Jiang, Aldo M Roccaro, Irene M Ghobrial

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: